Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.53 |
| ▸ | DRD2 | P14416 | 5/20 | 0.53 |
| ▸ | DRD3 | P35462 | 5/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.43 |
| ▸ | CASP5 | P51878 | 1/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7958587 | 0.82 | POLB (0.56) | DRD4DRD2DRD3ACHEPOLB | |
| SCHEMBL17108787 | 0.78 | SMN1; SMN2 (0.50) | DRD4DRD2DRD3KDM4E | |
| SCHEMBL1880665 | 0.78 | SMN1; SMN2 (0.54) | KDM4EGFER | |
| SCHEMBL23501608 | 0.77 | ALDH1A1 (0.46) | DRD4DRD2DRD3POLBKDM4E | |
| SCHEMBL29933818 | 0.77 | MC4R (0.47) | DRD4DRD2DRD3KDM4ECHKA | |
| SCHEMBL29934142 | 0.77 | ALDH1A1 (0.46) | DRD4DRD2DRD3POLBKDM4E | |
| SCHEMBL29934322 | 0.77 | HRH3 (0.47) | KDM4E | |
| SCHEMBL112800 | 0.77 | MC4R (0.47) | DRD4DRD2DRD3KDM4ECHKA | |
| SCHEMBL114033 | 0.77 | HRH3 (0.47) | KDM4E | |
| SCHEMBL3603185 | 0.77 | DRD4 (0.59) | DRD4DRD2DRD3KDM4ECASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | DRD4 3374/4885DRD2 1927/4885DRD3 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.